laboratori corpor america hold
usd oct pm et
summari clinic laboratori organ offer broad rang test servic
nation network laboratori
price-to-earnings oper ep
risk assess reflect lh leadership posit
larg matur industri broad geograph servic area
client state divers balanc
payer mix howev note uncertainti
surround reimburs rate futur regul
present modest risk compani
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori lh marketscop see
lift target price base
multipl ep
ep vs exceed
estim rais ep
ep
revenu grew
billion fuel acquisition-rel growth
organ growth off-set
partial busi disposit foreign
currenc translat diagnost
busi revenu per requisit exclud
impact divestitur increas
despit neg impact
increas come
acquisit revenu covanc drug
yoy billion howev cdd organ
growth fell bp short
expect encourag hear
lh remain track launchpad
initi help lh maintain
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
laboratori corpor america hold
laboratori director
corpor overview laboratori corpor america lh one two largest independ
 clinic laboratori clinic laboratori test use medic profession routin test
patient diagnosi monitor treatment diseas lh provid comprehens clinic
laboratori end-to-end drug develop servic two busi segment labcorp
diagnost lcd covanc drug develop cdd
compani laboratori servic involv test bodili fluid human tissu lh offer
nearli differ test consist routin test specialti test refer
esoter frequent administ routin test includ blood chemistri analys
urinalysi blood cell count thyroid test pap test hemoglobin test compani esoter
test includ test infecti diseas allergi diagnost genet ident oncolog
compani provid diagnost drug develop technology-en solut
million patient encount per year compani typic process test million
patient specimen per week also support clinic trial activ approxim countri
industry-lead central laboratori preclin clinic develop busi gener
safeti efficaci data support drug approv compani
cdd busi collabor novel drug approv food drug
administr fda includ novel rare orphan diseas drug
novel oncolog drug addit cdd involv develop current top
drug market measur sale revenu
lh provid test servic broad rang health care provid includ independ physician
hospit hmo manag care group well government institut test
servic bill parti physician author person order test
payor direct patient includ insur compani manag care organ
corpor strategi lh aim expand role health care focus key strateg initi
support custom transit value-bas care streamlin drug develop process
creat lead differenti consum experi addit lh believ continu
consolid healthcar compani strong relationship hospit health system
allow one largest provid laboratori test servic provid lead solut help
improv patient outcom reduc healthcar cost health system increasingli becom focal
point coordin patient care
protect access medicar act pama reimburs test price cut
maximum clf clinic laboratori fee
schedul reimburs rate cut maximum amount
disproportion affect small lab financi pressur lab attract acquisit opportun
lh think opportunist lab acquisit key driver lh growth next year
organ growth could achiev increas number higher-pr esoter test offer
competit landscap lh estim clinic laboratori test industri gener
revenu approxim billion clinic laboratori industri consist primarili three type
provid hospital-bas laboratori physician-offic laboratori independ clinic
anatom patholog laboratori oper lcd clinic laboratori busi
intens competit center medicar medicaid servic depart
human servic hh estim approxim
hospital-bas laboratori approxim physician-offic laboratori
independ clinic laboratori lcd compet laboratori believ
compani largest competitor also publicly-trad
signific consolid past decad industri
financi trend revenu increas year-over-year billion repres
five-year compound annual growth rate compound-annual-growth-rate sale growth aid significantli
recent year acquisit numer smaller lab exampl revenu growth due
acquisit organ growth adjust ep increas year-over-year
reflect five-year compound-annual-growth-rate approxim march compani
elev net debt capit ratio moder net debt trailing-twelve-month ebitda
ratio
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
lh fairli valu
neutral sinc octob technic indic lh
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
outlook health care servic
sub-industri next year posit
base key assumpt
economi current late stage
econom cycl mean expect
slowdown econom growth mani
firm within sub-industri like
see sustain demand servic even
face weaker econom condit
signific advers chang
oper competit environ
sub-industri recent pressur
headlin risk relat legisl
regulatori propos medicare-for-al
amazon potenti disrupt health
care sector headlin unlik
evolv real threat profit
health care servic firm near
futur analysi
sub-industri under-perform broader
market recent due pressur uniqu
benefit manag pbm hurt
lower level drug price inflat
increas pressur third parti payer
partial allevi high
firm issu find
see opportun health care servic
firm address take advantag
recent pressur face
exampl major pbm merg
major insur off-set pressur
aet ci acquir express script
esrx lab servic provid
opportun acquir smaller lab gain
scale smaller lab like falter
pressur continu signific
back topic headlin risk democrat
took control hous repres
novemb mid-term elect
result chang dynam
washington republican
domin preced two year
coupl key democrat candid
becom law would like lower
averag rate health care servic
henc substanti advers impact firm
sub-industri howev think
almost-zero chanc becom realiti
near futur
anoth headlin risk potenti repeal
afford act instig
judg texa rule
unconstitut oppon
appeal decis current expect
upheld upon appeal although
decis could take coupl year
reach repeal
expect neg impact health care
servic benefit
increas insur coverag past
sever year
year-to-d septemb
increas composit
 health servic
increas vs decreas
 composit index
base index
five-year market price perform oct
note sector sub-industri inform base
past perform indic futur perform
reli upon
laboratori corpor america
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
corpor america lower price target
base ep estim lh like
primari competitor lower revenu
earn outlook late novemb lh guid investor toward
adjust ep vs previou rang lh
revis outlook due lower-than-expect volum growth result
slower growth refer direct-to-consum genet test lower referr
volum hospit health system volum declin upcom
loss certain manag care plan advers weather lower ep
ep expect sale
growth compar prior estim sale growth
corpor america lower target
ep estim multipl near
averag lh five-year forward pe rang ep
vs lower estim larg ep
neg impact ransomwar attack lh hurrican
florenc lower ep ep
sale increas billion driven primarili acquisit
covanc drug develop cdd segment diagnost segment
revenu report decreas lh divest food solut
busi august exclud dispos busi revenu per
requisit decreas total volum increas compris
organ acquisit cdd segment
revenu sale growth compris organ
analyst research note compani news
pm et cfra keep hold opinion share laboratori corpor
america lift target price base
multipl ep ep vs
exceed estim rais ep
ep revenu grew billion
fuel acquisition-rel growth organ growth off-set
partial busi disposit foreign currenc translat
diagnost busi revenu per requisit exclud impact
divestitur increas despit neg impact
reimburs cut test requisit volum increas come
acquisit revenu covanc drug develop busi cdd
increas yoy billion howev cdd organ growth fell
bp short expect encourag hear lh remain
track launchpad initi help lh maintain
pm et cfra reiter hold opinion share laboratori
corpor america lift target price
base multipl lh averag ep
estim ep vs beat estim
rais ep maintain ep
revenu grew billion exclud disposit
busi revenu grew roughli line expect
diagnost busi revenu per requisit exclud impact
divestitur increas despit neg impact
reimburs cut relat protect access medicar act pama
test requisit volum declin organ much
wors key competitor organ volum growth organ sale
growth covanc drug develop busi weaker
expect lh adjust oper margin declin
prior-year period larg due pama /kevin huang cfa
pm et cfra maintain hold opinion share laboratori corpor
america lift target price base
multipl lh averag ep estim
lift ep lower ep
ep vs lower estim
revenu billion billion prior-year period
primarili divestitur unfavor currenc translat
organ basi revenu grew diagnost busi revenu per
requisit exclud impact divestitur decreas
better-than-expect due favor mix organ sale growth
covanc drug develop busi cdd expect
larg pass-through revenu year-over-year quarter
exclud pass-through revenu organ revenu growth cdd in-lin
compani full year guidanc rang /kevin huang cfa
pm et cfra keep hold opinion share laboratori corpor
america hold rais price target base
multipl lh three-year averag ep
ep vs lower estim initi
ep revenu billion increas larg
driven organ growth lh adjust oper margin
lower price tie
implement pama busi disposit higher personnel cost
partial offset headwind launchpad busi improv
initi sale labcorp diagnost segment declin
year-over-year covanc drug develop segment achiev
growth revenu diagnost test price continu
neg impact second round pama price cut yet present
lh opportun acquir smaller fail lab februari board
author repurchas billion stock /kevin huang cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
fiscal year analyst estim lh earn
usd quarter fiscal year lh
announc earn per share usd repres
total revenu estim fiscal year
analyst estim lh earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
laboratori corpor america hold
